Nanomaterials Technology Pte Ltd. (NMT), of Singapore, said it inked an agreement with Cao Pharmaceuticals Inc., of Houston, for a worldwide license to develop and market CZ-48, a anti-cancer drug jointly developed by NMT and Cao. CZ-48 is an analogue of camptothecin, a topoisomerase I inhibitor and prodrug that is activated as it enters tumor cells.